The probabilities were:
for relief in 2 hours, 57.4% with oral sumatriptan and 84.8% with SC sumatriptan;
for recurrence within 24 hours, 39.5% with oral sumatriptan and 41% with SC sumatriptan;
92% for enduring an attack after unsuccessful treatment with first dose;
8% for a visit to the ED;
99.8% for migraine relief at the ED; and
0.2% for hospitalisation during an ED visit.